Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carmustine Wafer in Recurrent Malignant Glioma (Phase III)
CTR20131097Phase 3Active
- Sponsor
- Shandong Lanjin Bioengineering
- Start
- Apr 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of carmustine in malignant glioma, glioblastoma (GBM), anaplastic astrocytoma (AA), sponsored by Shandong Lanjin Bioengineering. Started Apr 2014; status: active.
02
Drugs
carmustine
03
Conditions
malignant gliomaglioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on CTR20131097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131097.